vadimezan has been researched along with Carcinoma, Anaplastic in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bertelsen, LB; Bohn, AB; Falborg, L; Horsman, MR; Shen, YY; Stødkilde-Jørgensen, H | 1 |
| Minton, NP | 1 |
| Chung, YL; Clark, S; Griffiths, JR; Kelland, LR; Madhu, B; McPhail, LD; Robinson, SP | 1 |
1 review(s) available for vadimezan and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Clostridia in cancer therapy.
Topics: Animals; Antineoplastic Agents; Aziridines; Carcinoma; Clostridium; Cytosine Deaminase; Drug Delivery Systems; Humans; Mice; Neoplasms; Nitroreductases; Prodrugs; Spores, Bacterial; Xanthones | 2003 |
2 other study(ies) available for vadimezan and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Treatment with a vascular disrupting agent does not increase recruitment of indium labelled human endothelial outgrowth cells in an experimental tumour model.
Topics: Angiogenesis Inhibitors; Animals; Breast Neoplasms; Carcinoma; Cell Movement; Cell Survival; Cell Tracking; Cells, Cultured; Disease Models, Animal; Endothelial Cells; Female; Fetal Blood; Humans; Indium Radioisotopes; Mice; Mice, Nude; Stilbenes; Xanthones | 2014 |
Tumor dose response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy.
Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Membrane; Colonic Neoplasms; Dose-Response Relationship, Drug; Energy Metabolism; Magnetic Resonance Spectroscopy; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Transplantation, Heterologous; Xanthones | 2005 |